Virology News and Research

Latest Virology News and Research

Okairos to commence novel RSV vaccine Phase I clinical trial

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children.

25 Feb 2013

HIV epidemics and extra-couple relationships: an interview with Steve Bellan, University of Texas

The epicentre of the HIV pandemic is in sub-Saharan Africa, though prevalence of infection varies dramatically between countries for reasons not completely understood.

25 Feb 2013

Duke researchers focus on deadly math behind mutated genes and damaged cells that drive cancer

Two Duke researchers are focusing on the deadly mathematics behind the mutated genes and damaged cells that drive cancer.

25 Feb 2013

Death toll from SARS-like virus rises to 7

"Another person suffering from a SARS-like virus has died in Saudi Arabia, the World Health Organization said Thursday, bringing the worldwide number of fatalities from the mystery illness to seven," Agence France-Presse reports.

24 Feb 2013

Researchers identify new function for matriptase enzyme

Dr. Martin Richter (pharmacology), investigator with the Centre de recherche clinique Étienne-Le Bel (CRCELB) at the Centre hospitalier universitaire de Sherbrooke (CHUS) and professor in the Faculty of Medicine and Health Sciences of the Université de Sherbrooke (UdeS), and his collaborators have identified a new function of the enzyme matriptase, present in the human respiratory system, that can activate a viral protein involved in infections caused by the H1N1 influenza (or flu) virus.

24 Feb 2013

New drug proves to be effective in preventing spread of different flu strains

The new drug has been proven to be effective in preventing the spread of different strains of influenza in laboratory models - including resistant strains of the virus.

24 Feb 2013

Washington University creates new type of air-cleaning technology

Washington University engineering researchers have created a new type of air-cleaning technology that could better protect human lungs from allergens, airborne viruses and ultrafine particles in the air.

23 Feb 2013

U.S. health officials outline new policies for funding research on H5N1 avian flu, other potentially dangerous agents

"U.S. health authorities on Thursday outlined the conditions for funding research on the H5N1 bird flu virus a month after scientists lifted a yearlong pause on the work that was imposed amid concerns it could be used by terrorists," Bloomberg reports.

23 Feb 2013

New drug to safeguard against epidemic and pandemic flu strains

CSIRO scientists have helped to design a new drug to safeguard against epidemic and pandemic flu strains – as published in Science today.

22 Feb 2013

New molecular compounds can kill the influenza virus

Simon Fraser University virologist Masahiro Niikura and his doctoral student Nicole Bance are among an international group of scientists that has discovered a new class of molecular compounds capable of killing the influenza virus.

22 Feb 2013

Blaze Bioscience completes $8.5 million Series A financing

Blaze Bioscience, Inc., a biotechnology company dedicated to developing innovative products to improve the lives of cancer patients, today announced the completion of a Series A financing totaling $8.5 million and bringing the total funds raised since inception to $9.8 million.

22 Feb 2013

Viewpoints: Holtz-Eakin and Roy offer prescription to fix health law; Iowa lawmakers opposed to Medicaid expansion should give up their coverage

Over nearly a century, progressives have pressed for a national, single-payer healthcare system. When it comes to health reform, what have conservatives stood for? For far too long, conservatives have failed to coalesce around a long-term vision of what a free-market healthcare system should look like. ... Obamacare is the logical byproduct of this conservative policy neglect.

22 Feb 2013

Researchers identify second B-cell attachment receptor for Epstein-Barr virus

Epstein-Barr virus (EBV) affects more than 90 percent of the population worldwide and was the first human virus found to be associated with cancer. Now, researchers from Beth Israel Deaconess Medical Center (BIDMC) have broadened the understanding of this widespread infection with their discovery of a second B-cell attachment receptor for EBV.

21 Feb 2013

Sixth death from novel coronavirus recorded in Britain

"A British man infected with a new virus from the same family as SARS has died, health officials said on Tuesday, bringing the worldwide death toll from the previously unknown disease to six," Reuters reports.

21 Feb 2013

Daclatasvir has two primary modes of action against HCV

A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs - within 12 hours of treatment.

21 Feb 2013

Immunotherapy could be answer to treating novel coronavirus

Investigation into the mechanism of action of the novelcoronavirus HCoV-EMC, which recently emerged in the Middle East, has revealed that although human bronchial epithelia are very susceptible to infection with the virus, interferon I and III were both able to significantly reduce its replication in cell culture.

20 Feb 2013

Healthy adults with shorter telomere length more likely to develop upper respiratory infection

Among healthy adults who were administered a cold virus, those with shorter telomere length (a structure at the end of a chromosome) in certain cells were more likely to develop experimentally-induced upper respiratory infection than participants with longer telomeres, according to results of preliminary research published in the February 20 issue of JAMA.

20 Feb 2013

Working toward polio eradication in 2018

"Since the eradication of smallpox in the late 1970s, no other diseases have followed suit; the goal that has come closest so far is eradication of polio," a Lancet Infectious Diseases editorial states, noting that in 2012 only about 250 people were infected with polio worldwide.

20 Feb 2013

Study may help design better DAA drug cocktails to treat HCV

Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs.

20 Feb 2013